What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease?

Mansour, Asieh; Hekmatdoost, Azita; Mirmiran, Parvin

doi:10.1111/1751-2980.12751

Cited by 4 publications

(4 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metformin, a treatment option of choice for T2DM, has been shown to lessen steatosis in individuals with NASH and to avoid liver events in T2DM patients with advanced NASH [ 21 ]. Liraglutide has been shown in studies to have a favorable impact on NASH and the development of fibrosis by lowering body weight, even in patients who do not have T2DM [ 42 ]. The thiazolidinediones group, which includes the peroxisome proliferator-activated receptor (PPAR) agonists rosiglitazone and pioglitazone, has anti-steatotic, anti-inflammatory, and to a lesser extent, therapeutic benefits in NAFLD [ 42 ].…”

Section: Reviewmentioning

confidence: 99%

“…Liraglutide has been shown in studies to have a favorable impact on NASH and the development of fibrosis by lowering body weight, even in patients who do not have T2DM [ 42 ]. The thiazolidinediones group, which includes the peroxisome proliferator-activated receptor (PPAR) agonists rosiglitazone and pioglitazone, has anti-steatotic, anti-inflammatory, and to a lesser extent, therapeutic benefits in NAFLD [ 42 ]. In a phase 2 study, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) showed improvement in liver histology in individuals with NASH [ 20 ], in addition to improvement in cardiovascular and all-cause mortality in high-risk T2DM patients.…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review

Zaman¹,

Sultana²,

Dey³

et al. 2022

Cureus

View full text Add to dashboard Cite

In recent times, nonalcoholic fatty liver disease (NAFLD) has been considered one of the major causes of liver disease across the world. NAFLD is defined as the deposition of triglycerides in the liver and is associated with obesity and metabolic syndrome. Hyperinsulinemia, insulin resistance (IR), fatty liver, hepatocyte injury, unbalanced proinflammatory cytokines, mitochondrial dysfunction, oxidative stress, liver inflammation, and fibrosis are the main pathogenesis in NAFLD. Recent studies suggest that the action of intestinal microbiota through chronic inflammation, increased intestinal permeability, and energy uptake plays a vital role in NAFLD. Moreover, polycystic ovarian syndrome also causes NAFLD development through IR. Age, gender, race, ethnicity, sleep, diet, sedentary lifestyle, and genetic and epigenetic pathways are some contributing factors of NAFLD that can exacerbate the risk of liver cirrhosis and hepatocellular carcinoma (HCC) and eventually lead to death. NAFLD has various presentations, including fatigue, unexplained weight loss, bloating, upper abdominal pain, decreased appetite, headache, anxiety, poor sleep, increased thirst, palpitation, and a feeling of warmth. Some studies have shown that NAFLD with severe coronavirus disease 2019 (COVID-19) has poor outcomes. The gold standard for NAFLD diagnosis is liver biopsy. Other diagnostic tools are imaging tests, serum biomarkers, microbiota markers, and tests for extrahepatic complications. There are no specific treatments for NAFLD. Therefore, the main concern for NAFLD is treating the comorbid conditions such as anti-diabetic agents for type 2 diabetes mellitus, statins to reduce HCC progression, antioxidants to prevent hepatocellular damage, and bariatric surgery for patients with a BMI of >40 kg/m 2 and >35 kg/m 2 with comorbidities. Lifestyle and dietary changes are considered preventive strategies against NAFLD advancement. Inadequate treatment of NAFLD further leads to cardiac consequences, sleep apnea, chronic kidney disease, and inflammatory bowel disease. In this systematic review, we have briefly discussed the risk factors, pathogenesis, clinical features, and numerous consequences of NAFLD. We have also reviewed various guidelines for NAFLD diagnosis along with existing therapeutic strategies for the management and prevention of the disease.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review

Zaman¹,

Sultana²,

Dey³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…À ce jour, il n'y a aucune thérapie pharmacologique autorisée pour traiter la SHNA. Cependant, plusieurs interventions ont été proposées pour la maîtriser (tableau 1) (7). Ces dernières mettent l'accent sur les modifications des habitudes de vie.…”

Section: Stratégies Thérapeutiquesunclassified

“…Interventions proposées pour la gestion de la stéatose hépatique non alcoolique (adapté de Mansour et coll. 2019 (7))…”

Section: Définition Et Origine De La Diète Cétogèneunclassified

La diète cétogène : bénéfique pour la stéatose hépatique non alcoolique ?

Sophasath

Mukaneza

Huard³

et al. 2020

nutrition

View full text Add to dashboard Cite

La diète cétogène, une diète riche en matières grasses et faible en glucides, originalement développée pour le traitement de l’épilepsie, est de plus en plus considérée pour le traitement de la stéatose hépatique non-alcoolique (SHNA), la maladie chronique du foie la plus prévalente dans les pays développés. Des études animales et humaines ont été menées afin d’élucider l’effet de la diète cétogène sur la perte de poids et la SHNA. Toutefois, la plupart des études sont limitées par leur petite taille d’échantillon et leur courte durée en plus du fait que plusieurs sont observationnelles empêchant ainsi d’établir un lien de causalité. Ainsi, la controverse demeure quant à un effet bénéfique potentiel de la diète cétogène sur les facteurs de risque cardiométaboliques et la SHNA indiquant un besoin d’études supplémentaires. À date, aucun consensus n’a été établi. Dans ce contexte, une intervention au niveau des habitudes de vie, incluant l’alimentation, de type méditerranéen, et l’exercice physique, tout en considérant l’image corporelle, semble être la stratégie de choix. Une perte de poids de 7-10% est la première ligne de traitement pour les gens souffrant de SHNA. Les diététistes professionnels sont essentiels et les mieux placés pour l’éducation et le traitement des patients atteints de SHNA.

show abstract

Corosolic Acid Attenuates Hepatic Lipid Accumulation and Inflammatory Response via AMPK/SREBPs and NF-κB/MAPK Signaling Pathways

et al. 2020

View full text Add to dashboard Cite

Corosolic acid (CA) is the main active component of Lagetstroemia speciosa and has been known to serve as several different pharmacological effects, such as antidiabetic, anti-oxidant, and anticancer effects. In this study, effects of CA on the hepatic lipid accumulation were examined using HepG2 cells and tyloxapol (TY)-induced hyperlipidemia ICR mice. CA significantly inhibited hepatic lipid accumulation via inhibition of SREBPs, and its target genes FAS, SCD1, and HMGCR transcription in HepG2 cells. These effects were mediated through activation of AMPK, and these effects were all abolished in the presence of compound C (CC, an AMPK inhibitor). In addition, CA clearly alleviated serum ALT, AST, TG, TC, low-density lipoprotein cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C) levels, and obviously attenuated TY-induced liver steatosis and inflammation. Moreover, CA significantly upregulated AMPK, ACC, LKB1 phosphorylation, and significantly inhibited lipin1, SREBPs, TNF-[Formula: see text], F4/80, caspase-1 expression, NF-[Formula: see text]B translocation, and MAPK activation in TY-induced hyperlipidemia mice. Our results suggest that CA is a potent antihyperlipidemia and antihepatic steatosis agent and the mechanism involved both lipogenesis and cholesterol synthesis and inflammation response inhibition via AMPK/SREBPs and NF-[Formula: see text]B/MAPK signaling pathways.

show abstract

What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease?

Cited by 4 publications

References 96 publications

A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review

A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review

La diète cétogène : bénéfique pour la stéatose hépatique non alcoolique ?

Corosolic Acid Attenuates Hepatic Lipid Accumulation and Inflammatory Response via AMPK/SREBPs and NF-κB/MAPK Signaling Pathways

Contact Info

Product

Resources

About